There were 808 press releases posted in the last 24 hours and 183,702 in the last 365 days.

Amyotrophic Lateral Sclerosis Pipeline: Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight

The pipeline of Amyotrophic Lateral Sclerosis is very vast and in the coming years, it is expected that the market will grow with the approval of late-stage products in the pipeline.

/EIN News/ -- Los Angeles, June 15, 2021 (GLOBE NEWSWIRE) -- Amyotrophic Lateral Sclerosis Pipeline: Current Treatments, Drug Pipeline and Clinical Trial Outlook | Insights by DelveInsight

The pipeline of Amyotrophic Lateral Sclerosis is very vast and in the coming years, it is expected that the market will grow with the approval of late-stage products in the pipeline.

DelveInsight’s Amyotrophic Lateral Sclerosis (ALS) Pipeline Insights report offers exhaustive coverage of the emerging therapies and landscape in different stages of development from pre-clinical till late-stage, along with dormant, inactive, and abandoned therapeutic agents. 

Some of the key highlights from the Amyotrophic Lateral Sclerosis Pipeline report:

  • Amyotrophic Lateral Sclerosis Pipeline report offers a rich analysis of 100+ key players and 100+ key therapies.
  • Amyotrophic Lateral Sclerosis pipeline comprises therapies in different stages of the clinical phase such as BIIB067, ANX005, AMX0035, MN-166, BLZ945, AP-101, AS-202, Arimoclomol, ALZT-OP1a, AT1501, HK001, Q-Cells, and several others expected to get launched in the next decade. 
  • Some of the key companies engaged in expanding the Amyotrophic Lateral Sclerosis Pipeline are Biogen, Annexon Biosciences, Amylyx Pharmaceuticals, MediciNova, Novartis, AL-S Pharma, Acurastem, Orphazyme, AZTherapies, ALS TDI, Everfront Biotech, Q Therapeutics, among others.
  • DelveInsight estimates that the AMX0035 is expected to emerge as the trailblazer as the 24-week CENTAUR study comprising 137 participants with ALS met its primary endpoint of slowing ALS progression, as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R) and Amylyx Pharmaceuticals has announced its intention to submit a marketing authorization application for its investigational amyotrophic lateral sclerosis (ALS) therapy AMX0035 to the European Medicines Agency (EMA) by the end of 2021.
  • In May 2021, Seelos Therapeutics announced it has received European Orphan Drug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). 
  • In May 2021, Aeterna Zentaris announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). 
  • In May 2021, Orphazyme announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints to show benefit in people living with ALS. No important safety signals were reported in the trial. 
  • In March 2021, Retrotope announced that the first patient has been dosed in a multicenter Phase 2 clinical trial evaluating RT001, the company’s lead development candidate, in patients with amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). 

Request for Sample to know more about the therapies that are set to add maximum revenue @ Amyotrophic Lateral Sclerosis Emerging Therapies and Forecast 

The Amyotrophic Lateral Sclerosis Pipeline reports lay down a complete picture of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space and growth prospects across the Amyotrophic Lateral Sclerosis domain.

Amyotrophic Lateral Sclerosis: Overview

Amyotrophic Lateral Sclerosis is one of the groups of disorders known as motor neuron diseases, characterized by the progressive degeneration of nerve cells (motor neurons) in the brain and spinal cord eventually leading to their death. The condition hampers the communication between the nervous system and voluntary muscles of the body thus, affecting both the upper and lower motor neurons.

For more information on emerging drugs, visit ALS Pipeline Analysis 

Amyotrophic Lateral Sclerosis Pipeline Drugs 

Drug Company Phase MoA RoA
BIIB067 Biogen Phase III Superoxide dismutase inhibitors  Intrathecal
ANX005 Annexon Biosciences Phase II Complement C1 inhibitors Intravenous
AMX0035 Amylyx Pharmaceuticals Phase II/III Ammonia scavengers; Histone deacetylase inhibitors; Phosphotransferase inhibitors Oral
MN-166 MediciNova Phase II/III Astrocyte inhibitors; Cytokine modulators; Glial cell modulators; Leukotriene receptor antagonists Oral
BLZ945 Novartis Phase II Macrophage colony-stimulating factor receptor antagonists Oral
AP-101 AL-S Pharma Phase I Superoxide dismutase inhibitors Intravenous
AS-202 Acurastem Preclinical PIKFYVE protein inhibitors NA
Arimoclomol Orphazyme Phase III Heat shock transcription factor stimulants Oral
ALZT-OP1a AZTherapies Phase II Glial cell modulators; Mast cell stabilizers Inhalation
AT1501 ALS TDI Phase II CD40 ligand inhibitors Intravenous
HK001 Everfront Biotech Phase I Everfront Biotech Oral
Q-Cells Q Therapeutics Preclinical Cell replacements NA
Verdiperstat Biohaven Pharmaceuticals Phase II/III Peroxidase inhibitors Oral
NPT 520-34 Neuropore Therapies Phase I 1 Phosphatidylinositol 3 kinase modulators; Autophagy stimulants; Organic anion transport protein 3 inhibitors Oral

Request for Sample to know more @ Amyotrophic Lateral Sclerosis Pipeline Analysis, Key Companies and Futuristic Trends 

ALS Therapeutics Assessment 

The Amyotrophic Lateral Sclerosis Pipeline report proffers detailed insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

  • Mono
  • Combination

By Stage

  • Discovery 
  • Pre-clinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • Pre-registration

By Molecule Type 

  • Gene therapies
  • Small molecule
  • Vaccines
  • Polymers
  • Peptides
  • Monoclonal antibodies

By Route of Administration

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Oral
  • Parenteral
  • Subcutaneous
  • Inhalation
  • Intrathecal

By Mechanism of Action

  • Glial cell modulators
  • Histone deacetylase inhibitors
  • Heat shock transcription factor stimulants
  • C1q Inhibitors
  • Superoxide dismutase inhibitors
  • Immunomodulators

By Targets

  • Superoxide dismutase
  • Complement C1
  • Histone deacetylase
  • Macrophage colony-stimulating factor receptor
  • CD40 ligand
  • PIKFYVE protein

Get in touch with our Business executive for Informative Business Decisions, Licensing Services  and Consulting Solutions 

Scope of the ALS Pipeline Report

Coverage: Global
Key Players: Biogen, Annexon Biosciences, Amylyx Pharmaceuticals, MediciNova, Novartis, AL-S Pharma, Acurastem, Orphazyme, AZTherapies, ALS TDI, Everfront Biotech, Q Therapeutics, Biohaven Pharmaceuticals, Neuropore Therapies, Retrotope, Seelos Therapeutics, among others.
Key Amyotrophic Lateral Sclerosis Pipeline Therapies: BIIB067, ANX005, AMX0035, MN-166, BLZ945, AP-101, AS-202, Arimoclomol, ALZT-OP1a, AT1501, HK001, Q-Cells, Verdiperstat, NPT 520-34, RT001, SLS-005, among others.

Reach out @ Amyotrophic Lateral Sclerosis Pipeline: Novel therapies and Emerging technologies 

Table of Contents 

1 Report Introduction
2 Executive Summary
3 Amyotrophic Lateral Sclerosis Disease Overview
4 ALS Pipeline Therapeutics Comparative Analysis
5 Amyotrophic Lateral Sclerosis Therapeutic Assessment
6  Amyotrophic lateral sclerosis – DelveInsight’s Analytical Perspective
7 In-depth Commercial ALS Assessment
8 Amyotrophic Lateral Sclerosis Collaboration Deals
9 Late Stage ALS Products (Phase III)
10 Mid Stage ALS Products (Phase II)
11 Early Stage ALS Products (Phase I)
12 Pre-clinical and Discovery Stage ALS Products
13 Inactive Amyotrophic Lateral Sclerosis Pipeline Products 
14 Key Amyotrophic Lateral Sclerosis Products
15 Unmet Needs
16 Amyotrophic Lateral Sclerosis Market Drivers and Barriers
17 Future Perspectives and Conclusion
18 Analyst Views
19 Key Amyotrophic Lateral Sclerosis Companies
20 Appendix

Visit to know more of what’s covered @ ALS Emerging Therapies, Treatments and Ongoing Clinical Trials 

Related Reports

Amyotrophic Lateral Sclerosis Als Market
DelveInsight's "Amyotrophic lateral sclerosis (ALS) - Market Insights, Epidemiology, and Market Forecast-2030" report.

Acute Coronary Syndrome Market
DelveInsight's "Acute Coronary Syndrome - Market Insights, Epidemiology, and Market Forecast-2030" report.

Acute Ischemic Stroke Ais Market
DelveInsight's "Acute ischemic stroke (AIS) - Market Insights, Epidemiology, and Market Forecast-2030" report.

Cervical Dystonia Market
DelveInsight's "Cervical Dystonia - Market Insights, Epidemiology, and Market Forecast-2030" report.

Chronic Neuropathic Pain Market
DelveInsight's "Chronic Neuropathic Pain - Market Insights, Epidemiology, and Market Forecast-2030" report.

Charcot Marie Tooth Disease Market
DelveInsight's "Charcot-Marie-Tooth Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.

Related Posts 

10 Most Promising Drugs In The Amyotrophic Lateral Sclerosis Treatment Landscape
Burden And The Impact Of Mental Health 
Schizophrenia Market and Key Companies 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News 


Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com

Primary Logo